Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Evaluate the Safety and Tolerability of CE211NS21 in Patients With AQP4-IgG-positive NMOSD Relapse
2026. dec. 1.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publikáció
The Balance Between Immune Activation and Tolerance in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorders and MOG Antibody-Associated Disease.
2026. okt. 22.· Immunology and cell biology· PUBMED
Publikáció
Investigation of Complement Activation and Cytokine Signatures in AQP4+ NMOSD, MOGAD, and MS.
2026. okt. 21.· Annals of clinical and translational neurology· PUBMED
Publikáció
Phase-associated differences in perivascular and glymphatic-related MRI markers in AQP4-IgG-seropositive neuromyelitis Optica spectrum disorder: A cross-sectional study.
2026. okt. 21.· Multiple sclerosis and related disorders· PUBMED
Publikáció
Progressive hemifacial atrophy, AQP4-positive NMOSD and suspected Sjögren's syndrome: five-year relapse-free follow-up during rituximab therapy.
2026. okt. 21.· Acta neurologica Belgica· PUBMED
Publikáció
Differential Trajectories of Brain Atrophy in Multiple Sclerosis, MOGAD, and AQP4 + NMOSD: The Role of Disease Activity in MOGAD.
2026. okt. 20.· Neurology· PUBMED
Publikáció
AQP4 antibody-induced astrocyte injury reshapes CNS immune architecture in a combined EAE-AQP4-IgG model of neuromyelitis optica spectrum disorder.
2026. okt. 19.· Frontiers in immunology· PUBMED
Publikáció
Autoimmune comorbidity profiles in MOGAD and AQP4-NMOSD: a real-world evidence study of top 10 autoimmune disorders across the pre- and post-COVID-19 eras.
2026. okt. 17.· Multiple sclerosis and related disorders· PUBMED
Publikáció
Characterization of distinct cognitive domain patterns in AQP4-IgG-positive NMOSD: A MoCA-based factor analysis and risk profiling.
2026. okt. 17.· Multiple sclerosis and related disorders· PUBMED
Publikáció
Clinical phenotype and treatment response in AQP4-IgG-positive NMOSD and MOGAD: insights from the Italian I-MS&RD registry.
2026. okt. 16.· Journal of neurology· PUBMED
Publikáció
Cerebral Attack With Cortical-Leptomeningeal Involvement and Seizures in AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
2026. okt. 15.· Internal medicine (Tokyo, Japan)· PUBMED
Publikáció
Astrocytic and Axonal Injury Biomarkers in AQP4 Antibody-Positive NMOSD: Insights From PREVENT and CHAMPION-NMOSD.
2026. okt. 8.· Neurology(R) neuroimmunology & neuroinflammation· PUBMED
Publikáció
Efficacy and Safety of Multidisciplinary Sandwich Regimen in AQP4-IgG+ NMOSD With Preconception B-Cell Depletion During Perigravidity.
2026. okt. 1.· CNS neuroscience & therapeutics· PUBMED
Publikáció
Serum GFAP and Age Accurately Distinguish AQP4-IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack.
2026. okt. 1.· European journal of neurology· PUBMED
Publikáció
Why repair fails in AQP4-IgG-positive neuromyelitis optica spectrum disease: an astrocyte-centered framework for remyelination and neuroaxonal preservation.
2026. szept. 29.· Frontiers in immunology· PUBMED
Publikáció
Case Report: Unplanned pregnancy during treatment with inebilizumab in patients with AQP4-IgG-seropositive NMOSD: report of two cases.
2026. szept. 24.· Frontiers in immunology· PUBMED
Publikáció
Diagnostic Utility of Novel and Established Spinal MRI Signs in AQP4-IgG-Seropositive NMOSD Myelitis.
2026. szept. 21.· Neurology· PUBMED
Publikáció
Optimizing the management of AQP4 antibody-positive NMOSD: A Canadian consensus.
2026. szept. 21.· Multiple sclerosis and related disorders· PUBMED
Publikáció
Scutellarin attenuates high glucose-induced edema and inflammation in retinal Müller cells via AQP4/Kir4.1 restoration and TLR4/MyD88/NF-κB inhibition.
2026. szept. 18.· Frontiers in pharmacology· PUBMED
Publikáció
Comparative effectiveness of inebilizumab versus conventional immunotherapies in AQP4-IgG-positive NMOSD: a prospective cohort study with time-varying treatment effects.
2026. szept. 15.· Journal of neurology, neurosurgery, and psychiatry· PUBMED
Publikáció
Inter-attack serum GFAP and NfL remain stable over 9 years in AQP4 IgG NMOSD.
2026. szept. 14.· Journal of neurology, neurosurgery, and psychiatry· PUBMED
Vizsgálat
A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients
2026. szept. 1.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publikáció
IL-6 Receptor Blockade as Rescue Therapy in Acute Attacks of MOGAD and AQP4+NMOSD.
2026. szept. 1.· JAMA neurology· PUBMED
Publikáció
Multimodal assessment of sleep and regional brain volumes in AQP4-IgG-positive neuromyelitis optica spectrum disorder: An exploratory cross-sectional study.
2026. aug. 27.· Multiple sclerosis and related disorders· PUBMED
Publikáció
Inebilizumab in AQP4-Seropositive NMOSD: One-Year Follow-Up From a Multicenter, Real-World Study.
2026. aug. 23.· Annals of clinical and translational neurology· PUBMED
Publikáció
A systematic review and meta-analysis of the efficacy and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder.
2026. aug. 22.· Multiple sclerosis and related disorders· PUBMED
Publikáció
Clinical Significance and Changes in Levels of Serum BDNF, mBDNF, AQP4, proBDNF, and GSK3β in Individuals Diagnosed With Bipolar Disorder: A Cross-Sectional Study.
2026. aug. 11.· Health science reports· PUBMED
Publikáció
Clinical and serological features of systemic autoimmune overlap in AQP4-IgG positive neuromyelitis optica spectrum disorder: a Mexican cohort study.
2026. aug. 4.· Multiple sclerosis and related disorders· PUBMED
Preprint
2,6-diaminopurine enhances Aqp4 stop codon readthrough and AQP4 perivascular localization in the brain.
2026. aug. 4.· bioRxiv : the preprint server for biology· PUBMED
Publikáció
Ravulizumab rescue therapy in a refractory AQP4-positive neuromyelitis optica attack with extensive encephalomyelitis.
2026. aug. 3.· Revue neurologique· PUBMED